Cited by 240Immunotherapy and Immune ResponsesRNA Interference and Gene DeliverySARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Mechanism of action of mRNA-based vaccines

Iavarone, Carlo, O’hagan, Derek T., Yu, Dong, Delahaye, Nicolas F., Ulmer, Jeffrey B.·2017·Expert Review of Vaccines

DOI 10.1080/14760584.2017.1355245

Open this paper in CoChat — free account

Abstract

INTRODUCTION: The present review summarizes the growing body of work defining the mechanisms of action of this exciting new vaccine technology that should allow rational approaches in the design of next generation mRNA vaccines. Areas covered: Bio-distribution of mRNA, localization of antigen production, role of the innate immunity, priming of the adaptive immune response, route of administration and effects of mRNA delivery systems. Expert commentary: In the last few years, the development of RNA vaccines had a fast growth, the rising number of proof will enable rational approaches to improving the effectiveness and safety of this modern class of medicine.

Integrity signals

Registry

Crossref · 10.1080/14760584.2017.1355245

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 2×
“Wolff [2] demonstrated that uptake and expression of exogenous RNA can be achieved without a delivery system.”
Background
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Self-citation
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“Interaction among PRRs and PAMPs triggers the inflammatory response, the link between the innate immunity and the adaptive immunity [43].”
Background
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930

Show all 134 references

Research works printed but not linked: 5

Weissman D., 2015, Expert Vacc Rev
Vormehr M, 2015, J Immunol Res, 595363, 2015
Pepini T, 2017, Induction of an interferon-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design
Thoryk EA, 2016, Vaccines (Basel), 4
Wang WX, 2014, Yao Xue Xue Bao, 49, 1111

Sorted by citations

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 660
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
Self-citation
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 442
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich‐Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi‐Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 356
An Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Wang, F., Kream, R. M., & Stefano, G. B. (2020) · Medical Science Monitor · doi:10.12659/msm.924700 · Cited by 243
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 227
A trans-amplifying RNA vaccine strategy for induction of potent protective immunity
Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.009 · Cited by 212
Comparison of DNA and mRNA vaccines against cancer
Jahanafrooz, Z., Baradaran, B., Mosafer, J., Hashemzaei, M., Rezaei, T., Mokhtarzadeh, A., & Hamblin, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.003 · Cited by 202
Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
Teo, S. P. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900211009650 · Cited by 191
Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection
Lou, G., Anderluzzi, G., Schmidt, S., Woods, S., Gallorini, S., Brazzoli, M., Giusti, F., Ferlenghi, I., Johnson, R. N., Roberts, C. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.027 · Cited by 176
Self-citation
Nanotechnology Responses to COVID‐19
Ruiz‐Hitzky, E., Darder, M., Wicklein, B., Ruiz‐García, C., Martín‐Sampedro, R., del Real, G., & Aranda, P. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000979 · Cited by 175
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 171
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA
Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132
mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice
Zhuang, X., Qi, Y., Wang, M., Yu, N., Nan, F., Zhang, H., Tian, M., Li, C., Lu, H., & Jin, N. (2020) · Vaccines · doi:10.3390/vaccines8010123 · Cited by 132
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Lipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 133
mRNA vaccine trafficking and resulting protein expression after intramuscular administration
Hassett, K. J., Rajlic, I. L., Bahl, K., White, R. A., Cowens, K. B., Jacquinet, E., & Burke, K. E. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102083 · Cited by 128
Ex vivo pulsed dendritic cell vaccination against cancer
Gu, Y., Zhao, X., & Song, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0415-5 · Cited by 115
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 121
Vaccines and global health: In search of a sustainable model for vaccine development and delivery
Rappuoli, R., BLACK, S. B., & Bloom, D. E. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2888 · Cited by 105
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency
Anderluzzi, G., Lou, G., Woods, S., Schmidt, S., Gallorini, S., Brazzoli, M., Johnson, R., Roberts, C. W., O’Hagan, D. T., Baudner, B. C., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.008 · Cited by 100
Self-citation
Nanocarrier vaccines for SARS-CoV-2
Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 100
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections
Versteeg, L., Almutairi, M. M., Hotez, P. J., & Pollet, J. B. K. (2019) · Vaccines · doi:10.3390/vaccines7040122 · Cited by 94
Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 88
Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells
Verbeke, R., Lentacker, I., Breckpot, K., Janssens, J., Calenbergh, S. V., Smedt, S. C. D., & Dewitte, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b07660 · Cited by 85
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 80
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 73
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 72
Perspectives on RNA Vaccine Candidates for COVID-19
Borah, P., Deb, P. K., Al‐Shar’i, N. A., Dahabiyeh, L. A., Venugopala, K. N., Singh, V., Shinu, P., Hussain, S., Deka, S., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635245 · Cited by 67
Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice
Samsa, M. M., Dupuy, L. C., Beard, C. W., Six, C. M., Schmaljohn, C. S., Mason, P. W., Geall, A. J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.013 · Cited by 63
Self-citation
Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines
Anderluzzi, G., Lou, G., Gallorini, S., Brazzoli, M., Johnson, R., O’Hagan, D. T., Baudner, B. C., & Perrie, Y. (2020) · Vaccines · doi:10.3390/vaccines8020212 · Cited by 57
Self-citation
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
ROS‐Responsive Injectable Hydrogel Loaded with SLC7A11‐modRNA Inhibits Ferroptosis and Mitigates Intervertebral Disc Degeneration in Rats
Gao, T., Xu, G., Ma, T., Lu, X., Chen, K., Luo, H., Chen, G., Song, J. G., Ma, X., Fu, W. E., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401103 · Cited by 59
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure
Yoo, S. J., Kwon, T., & Lyoo, Y. S. (2018) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2018.7.1.1 · Cited by 58
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55
Advances in mRNA-Based Cancer Vaccines
Ni, L. (2023) · Vaccines · doi:10.3390/vaccines11101599 · Cited by 56
High-Resolution capillary electrophoresis separation of large RNA under non-aqueous conditions
Lu, T., Klein, L. J., Ha, S., & Rustandi, R. R. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.460875 · Cited by 53
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells
Kim, Y., Kim, H., Kim, E. H., Jang, H., Jang, Y., Chi, S.-G., Yang, Y., & Kim, S. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061271 · Cited by 50
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Nano-Microparticle Platforms in Developing Next-Generation Vaccines
Cappellano, G., Abreu, H., Casale, C., Dianzani, U., & Chiocchetti, A. (2021) · Vaccines · doi:10.3390/vaccines9060606 · Cited by 50
Messenger RNA chromatographic purification: advances and challenges
Xue, F., Su, Z. G., Cheng, Y., Ma, G., & Zhang, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464321 · Cited by 50
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 49
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines
Lim, C. M. L., Komarasamy, T. V., Adnan, N. A. A., Radhakrishnan, A. K., & Balasubramaniam, V. R. M. T. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13276 · Cited by 55
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Viral Glycoproteins Induce NLRP3 Inflammasome Activation and Pyroptosis in Macrophages
Eisfeld, H. S., Simonis, A., Winter, S., Chhen, J., Stroh, L. J., Krey, T., Koch, M., Theobald, S. J., & Rybniker, J. (2021) · Viruses · doi:10.3390/v13102076 · Cited by 44
Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics
Ishaqat, A., & Herrmann, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08484 · Cited by 42
Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation
Löffler, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663280 · Cited by 44
Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines
Lofano, G., Mallett, C. P., Bertholet, S., & O’Hagan, D. T. (2020) · npj Vaccines · doi:10.1038/s41541-020-00238-8 · Cited by 41
Self-citation
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2131767 · Cited by 37
Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
Bafaloukos, D. I., Gazouli, I., Koutserimpas, C., & Samonis, G. (2023) · Vaccines · doi:10.3390/vaccines11030636 · Cited by 44
Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions
Ramadan, E., Ismeal, A. A. A., & Naguib, Y. W. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14111092 · Cited by 42
Overview on LNP-mRNA encapsulation unit operation: Mixing technologies, scalability, and influence of formulation & process parameters on physico-chemical characteristics
Hourdel, L., Lebaz, N., Peral, F., Ripoll, M., Briançon, S., Bensaid, F., Luthra, S., & Cogné, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125297 · Cited by 37
Exploiting vita-PAMPs in vaccines
Blander, J. M., & Barbet, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.012 · Cited by 34
Polymeric nanostructure vaccines: applications and challenges
Simón‐Vázquez, R., Peleteiro, M., & González‐Fernández, Á. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1776259 · Cited by 35
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA
Samnuan, K., Blakney, A. K., McKay, P. F., & Shattock, R. J. (2022) · F1000Research · doi:10.12688/f1000research.75677.1 · Cited by 36
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33
Emerging advances in delivery systems for mRNA cancer vaccines
Jiang, Z., Xu, Y., Du, G., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.039 · Cited by 35
mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents
Roier, S., Prasad, V. M., McNeal, M., Lee, K. K., Petsch, B., & Rauch, S. (2023) · npj Vaccines · doi:10.1038/s41541-023-00790-z · Cited by 33
Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Sustainable vaccine development: a vaccine manufacturer's perspective
Rappuoli, R., & Hanon, E. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.04.019 · Cited by 32
mRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery
van Rijn, C. J. M., Vlaming, K. E., Reinout, A., Dekker, R. J., Poortinga, A. T., Breit, T. M., van Leeuwen, S. M., Ensink, W. A., van Wijnbergen, K., van Hamme, J. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35872-4 · Cited by 30
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity
Luo, X., McAndrews, K. M., Arian, K. A., Morse, S. J., Boeker, V., Kumbhar, S. V., Hu, Y., Mahadevan, K. K., Church, K. A., Chitta, S., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.017 · Cited by 30
Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy
Chen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 32
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
Vacunas frente a SARS-CoV-2 y piel
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
Lin, F., Lin, E. Z., Anekoji, M., Ichim, T. E., Hu, J. K., Marincola, F. M., Jones, L. D., Kesari, S., & Ashili, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04724-0 · Cited by 28
Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 31
Strategies to deliver RNA by nanoparticles for therapeutic potential
Cox, A., Lim, S. A., & Chung, E. J. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100991 · Cited by 28
Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects
Ferrari, D., Resta, C. D., Tomaiuolo, R., Sabetta, E., Pontillo, M., Motta, A., & Locatelli, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.020 · Cited by 26
Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development
Wu, B., Qi, Z., & Qian, X. (2023) · Viruses · doi:10.3390/v15040813 · Cited by 26
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26
Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis
Shahrear, S., & Islam, A. B. M. M. K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10515-4 · Cited by 24
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 30
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 25
Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines
Manara, C., Brazzoli, M., Piccioli, D., Taccone, M., D’Oro, U., Maione, D., & Frigimelica, E. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.028 · Cited by 23
SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology
Sahu, A. K., Sreepadmanabh, M., Rai, M., & Chande, A. G. (2021) · VirusDisease · doi:10.1007/s13337-021-00653-y · Cited by 23
Development of an RNA Expression Platform Controlled by Viral Internal Ribosome Entry Sites
Ko, H. L., Park, H., Kim, J., Kim, H., Youn, H., & Nam, J. (2019) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1811.11019 · Cited by 23
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 21
mRNA Vaccine - A New Cancer Treatment Strategy
Tan, T., Deng, S., Wu, B.-H., Yang, Q., Wu, M., Wu, H., Cao, C., & Xu, C. S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230222124424 · Cited by 22
A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 23

Authors: Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B.
Affiliations: GlaxoSmithKline (United States) (US)
Corresponding author: Iavarone, Carlo
ORCID: Yu, Dong
Venue: Expert Review of Vaccines
Publisher: Informa UK Limited
Published: 2017-07-28
Volume: 16
Issue: 9
Pages: 871-881
ISSN: 1476-0584 (ISSN-L)
1744-8395
DOI: 10.1080/14760584.2017.1355245
OpenAlex: W2736048901
Cited by: 234
References: 134
Citations by year: 2026: 13 · 2025: 29 · 2024: 34 · 2023: 33 · 2022: 35 · 2021: 45 · 2020: 26 · 2019: 13 · 2018: 5 · 2017: 1
FWCI: 1.27
Type: journal article
Language: en
Open access: closed
Locations: Expert Review of Vaccines (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Defense Advanced Research Projects Agency
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: mRNA vaccines, vaccine mechanism of action, antigen localization, innate immunity, route of administration, mRNA delivery systems, vaccine design
MeSH terms: Humans, Immunity, Innate, RNA, Messenger, Vaccines, Drug Delivery Systems, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanism of action of mRNA-based vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks